摘要
非肥胖糖尿病/严重联合免疫缺陷(non-obese diabetes-SCID mice,NOD/SCID)小鼠具有T、B淋巴细胞联合免疫缺陷、NK细胞活性低下、无循环补体、巨噬细胞和抗原提呈细胞功能损害等特性,近年已成为人类肿瘤移植瘤的最佳研究模型。NOD/SCID鼠的人类血液系统肿瘤模型能够研究造血微环境、白血病细胞的分化调控机制和潜在的治疗靶点,并且建立在此平台上的体内药敏实验,可以指导临床化疗方案设计,目前已显示出突出的疗效。乳腺癌等实体瘤原代肿瘤组织的移植瘤模型,也显示出可复制人类肿瘤特点的优势。此外,NOD/SCID鼠可进行肿瘤干细胞的筛选和鉴定,并寻找针对肿瘤干细胞的特异性治疗靶点。目前的研究已展现了NOD/SCID鼠在肿瘤研究领域的广阔前景。
Non-obese diabetes-SCID mice (NOD/SCID) have not only immune function of T, B lymphocyte, but also circulation complement and microphage cells. Meanwhile, they have the characteristics of low activity of NK cells and damaged function of antigen presenting cells. Recently, this breed has become optimal xenograft model of human tumor. Human hematology tumor established in NOD/SCID mice could be investigated bematopoietic microenvironment, mechanism of differentiation and modulation of leukaemia cells and potential therapeutic targets. Besides, drug sensitivity experiments in vivo may instruct optimal chemotherapy projects. The primary cancer tissue xenograft model of solid tumor like breast cancer has showed the advantage of duplicating human cancer. In addition, researchers could filtrate and identify cancer stem cells by NOD/SCID mice, so the study of specific therapeutic targets of cancer progenitor cells is available. Now investigations have exhibited widely used of NOD/SCID mice in oncology.
出处
《中华肿瘤防治杂志》
CAS
2008年第4期307-310,共4页
Chinese Journal of Cancer Prevention and Treatment